Clinical implications of BRAF mutation in thyroid carcinoma

Trends in Endocrinology and Metabolism

Volumn 19, Issue 4, 2008, Pages 138-145

  Puxeddu, Efisio ^a   Durante, Cosimo ^b   Avenia, Nicola ^a   Filetti, Sebastiano ^b   Russo, Diego ^c  

^a UNIVERSITY OF PERUGIA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN SERINE THREONINE KINASE;

ADVANCED CANCER; CANCER DIAGNOSIS; CANCER STAGING; CANCER THERAPY; DEATH; DIAGNOSTIC ACCURACY; DRUG TARGETING; GENE EXPRESSION; GENE MUTATION; HUMAN; MOLECULAR EPIDEMIOLOGY; PAPILLARY THYROID CARCINOMA; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; STRATIFICATION; THYROID CARCINOMA;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, PAPILLARY; DRUG DELIVERY SYSTEMS; GENE FREQUENCY; HUMANS; MODELS, BIOLOGICAL; MOLECULAR DIAGNOSTIC TECHNIQUES; MUTATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; THYROID NEOPLASMS;

EID: 43049133793     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tem.2007.12.003     Document Type: Review

References (72)

1. Schlumberger M., et al. Non toxic goiter and thyroid neoplasia. In: Larsen P.R., et al. (Ed). Williams' Textbook of Endocrinology. 10th edn (2003), WB Saunders 457-490
2. National Cancer Institute (2004) Surveillance Research Program CSB Surveillance, Epidemiology and End Results (SEER) Program, November 2003 (edn), National Cancer Institute
3. Cooper D.S., et al. The American Thyroid Association Guidelines Taskforce. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 16 (2006) 109-142
4. Xing M. BRAF mutation in thyroid cancer. Endocr. Relat. Cancer 12 (2005) 245-262
5. Espinosa A.V., et al. Targeting BRAF in thyroid cancer. Br. J. Cancer 96 (2007) 16-20
6. Wellbrock C., et al. The RAF proteins take centre stage. Nat. Rev. Mol. Cell Biol. 5 (2004) 875-885
7. Davies H., et al. Mutations of the BRAF gene in human cancer. Nature 417 (2002) 949-954
8. Moretti S., et al. Biochemical and molecular characterization of the novel BRAF(V599Ins) mutation detected in a classic papillary thyroid carcinoma. Oncogene 25 (2006) 4235-4240
9. Ciampi R., et al. Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer. J. Clin. Invest. 115 (2005) 94-101
10. Wan P.T., et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116 (2004) 855-867
11. Kimura E.T., et al. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 63 (2003) 1454-1457
12. Melillo R.M., et al. The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. J. Clin. Invest. 115 (2005) 1068-1081
13. Mitsutake N., et al. BRAF mediates RET/PTC-induced mitogen-activated protein kinase activation in thyroid cells: functional support for requirement of the RET/PTC-RAS-BRAF pathway in papillary thyroid carcinogenesis. Endocrinology 147 (2006) 1014-1019
14. Ugolini C., et al. Presence of BRAF V600E in Very Early Stages of Papillary Thyroid Carcinoma. Thyroid 17 (2007) 381-388
15. Sedliarou I., et al. The BRAFT1796A transversion is a prevalent mutational event in human thyroid microcarcinoma. Int. J. Oncol. 25 (2004) 1729-1735
16. Kim T.Y., et al. The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma. Clin. Endocrinol. (Oxf.) 63 (2005) 588-593
17. Knauf J.A., et al. Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. Cancer Res. 65 (2005) 4238-4245
18. Lee J.H., et al. Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid: a meta-analysis. Cancer 110 (2007) 38-46
19. Fugazzola L., et al. Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature. Endocr. Relat. Cancer 13 (2006) 455-464
20. Kebebew E., et al. The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann. Surg. 246 (2007) 466-471
21. Trovisco V., et al. Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients' age but not with tumour aggressiveness. Virchows Arch. 446 (2005) 589-595
22. Adeniran A.J., et al. Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am. J. Surg. Pathol. 30 (2006) 216-222
23. Nikiforova M.N., et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J. Clin. Endocrinol. Metab. 88 (2003) 5399-5404
24. Yamashita S., and Saenko V. Mechanisms of disease: molecular genetics of childhood thyroid cancers. Nat. Clin. Pract. Endocrinol. Metab. 3 (2007) 422-429
25. Filetti S., et al. Nonsurgical approaches to the management of thyroid nodules. Nat. Clin. Pract. Endocrinol. Metab. 2 (2006) 384-394
26. Cohen Y., et al. Mutational analysis of BRAF in fine needle aspiration biopsies of the thyroid: a potential application for the preoperative assessment of thyroid nodules. Clin. Cancer Res. 10 (2004) 2761-2765
27. Salvatore G., et al. Analysis of BRAF point mutation and RET/PTC rearrangement refines the fine-needle aspiration diagnosis of papillary thyroid carcinoma. J. Clin. Endocrinol. Metab. 89 (2004) 5175-5180
28. Xing M., et al. Detection of BRAF mutation on fine needle aspiration biopsy specimens: a new diagnostic tool for papillary thyroid cancer. J. Clin. Endocrinol. Metab. 89 (2004) 2867-2872
29. Hayashida N., et al. A rapid and simple detection method for the BRAF(T1796A) mutation in fine-needle aspirated thyroid carcinoma cells. Thyroid 14 (2004) 910-915
30. Chung K.W., et al. Detection of BRAFV600E mutation on fine needle aspiration specimens of thyroid nodule refines cyto-pathology diagnosis, especially in BRAFV600E mutation-prevalent area. Clin. Endocrinol. (Oxf.) 65 (2006) 660-666
31. Rowe L.R., et al. Utility of BRAF V600E mutation detection in cytologically indeterminate thyroid nodules. Cytojournal 3 (2006) 10
32. Sapio M.R., et al. Detection of RET/PTC, TRK and BRAF mutations in preoperative diagnosis of thyroid nodules with indeterminate cytological findings. Clin. Endocrinol. (Oxf.) 66 (2007) 678-683
33. Kumagai A., et al. Clinical implications of pre-operative rapid BRAF analysis for papillary thyroid cancer. Endocr. J. 54 (2007) 399-405
34. Pizzolanti G., et al. Fine-needle aspiration molecular analysis for the diagnosis of papillary thyroid carcinoma through BRAF V600E mutation and RET/PTC rearrangement. Thyroid (2007). http://www.liebertonline.com/loi/thy 10.1089/thy.2007.0008
35. Tallini G. Molecular pathobiology of thyroid neoplasms. Endocr. Pathol. 13 (2002) 271-288
36. Fugazzola L., et al. BRAF mutations in an Italian cohort of thyroid cancers. Clin. Endocrinol. (Oxf.) 61 (2004) 239-243
37. Xu X., et al. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res. 63 (2003) 4561-4567
38. Puxeddu E., et al. BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas. J. Clin. Endocrinol. Metab. 89 (2004) 2414-2420
39. Riesco-Eizaguirre G., et al. The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I- targeting to the membrane. Endocr. Relat. Cancer 13 (2006) 257-269
40. Kim K.H., et al. Mutations of the BRAF gene in papillary thyroid carcinoma in a Korean population. Yonsei Med. J. 45 (2004) 818-821
41. Lee J.H., et al. BRAF mutation and AKAP9 expression in sporadic papillary thyroid carcinomas. Pathology 38 (2006) 201-204
42. Liu R.T., et al. No correlation between BRAFV600E mutation and clinicopathological features of papillary thyroid carcinomas in Taiwan. Clin. Endocrinol. (Oxf.) 63 (2005) 461-466
43. Namba H., et al. Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J. Clin. Endocrinol. Metab. 88 (2003) 4393-4397
44. Jo Y.S., et al. Influence of the BRAF V600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer. J. Clin. Endocrinol. Metab. 91 (2006) 3667-3670
45. Kim T.Y., et al. The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma. Clin. Endocrinol. (Oxf.) 65 (2006) 364-368
46. Xing M., et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J. Clin. Endocrinol. Metab. 90 (2005) 6373-6379
47. Lupi C., et al. Association of BRAF V600E mutation with poor clinicopathologic outcomes in 500 consecutive cases of papillary thyroid carcinoma. J. Clin. Endocrinol. Metab. 92 (2007) 4085-4090
48. Vasko V., et al. High prevalence and possible de novo formation of BRAF mutation in metastasized papillary thyroid cancer in lymph nodes. J. Clin. Endocrinol. Metab. 90 (2005) 5265-5269
49. Kim J., et al. Lymphatic mapping establishes the role of BRAF gene mutation in papillary thyroid carcinoma. Ann. Surg. 244 (2006) 799-804
50. Rodolico V., et al. BRAF(V600E) mutation and p27(kip1) expression in papillary carcinomas of the thyroid
51. Xing M. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr. Rev. 28 (2007) 742-762
52. Durante C., et al. BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. J. Clin. Endocrinol. Metab. 92 (2007) 2840-2843
53. Groussin L., and Fagin J.A. Significance of BRAF mutations in papillary thyroid carcinoma: prognostic and therapeutic implications. Nat. Clin. Pract. Endocrinol. Metab. 2 (2006) 180-181
54. Solit D.B., et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 439 (2006) 358-362
55. Ouyang B., et al. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo. Clin. Cancer Res. 12 (2006) 1785-1793
56. Salvatore G., et al. BRAF is a therapeutic target in aggressive thyroid carcinoma. Clin. Cancer Res. 12 (2006) 1623-1629
57. Mitsiades C.S., et al. Targeting BRAFV600E in thyroid carcinoma: therapeutic implications. Mol. Cancer Ther. 6 (2007) 1070-1078
58. Liu D., et al. Suppression of BRAF/MEK/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cancer cells expressing the V600E BRAF mutant. Clin. Cancer Res. 13 (2007) 1341-1349
59. Kim S., et al. Sorafenib inhibits the angiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice. Mol. Cancer Ther. 6 (2007) 1785-1792
60. Roberts P.J., and Der C.J. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 26 (2007) 3291-3310
61. Sebolt-Leopold J.S., and English J.M. Mechanisms of drug inhibition of signalling molecules. Nature 441 (2006) 457-462
62. Kolch W., et al. The role of Raf kinases in malignant transformation. Expert Rev. Mol. Med. 4 (2002) 1-18
63. Mitsutake N., et al. Conditional BRAFV600E expression induces DNA synthesis, apoptosis, dedifferentiation, and chromosomal instability in thyroid PCCL3 cells. Cancer Res. 65 (2005) 2465-2473
64. Mesa Jr. C., et al. Conditional activation of RET/PTC3 and BRAFV600E in thyroid cells is associated with gene expression profiles that predict a preferential role of BRAF in extracellular matrix remodeling. Cancer Res. 66 (2006) 6521-6529
65. Palona I., et al. BRAFV600E promotes invasiveness of thyroid cancer cells through nuclear factor kappaB activation. Endocrinology 147 (2006) 5699-5707
66. Liu D., et al. BRAF V600E maintains proliferation, transformation, and tumorigenicity of BRAF-mutant papillary thyroid cancer cells. J. Clin. Endocrinol. Metab. 92 (2007) 2264-2271
67. Giordano T.J., et al. Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis. Oncogene 24 (2005) 6646-6656
68. Frattini M., et al. Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer. Oncogene 23 (2004) 7436-7440
69. Porra V., et al. Silencing of the tumor suppressor gene SLC5A8 is associated with BRAF mutations in classical papillary thyroid carcinomas. J. Clin. Endocrinol. Metab. 90 (2005) 3028-3035
70. Hu S., et al. Association of aberrant methylation of tumor suppressor genes with tumor aggressiveness and BRAF mutation in papillary thyroid cancer. Int. J. Cancer 119 (2006) 2322-2329
71. Di Cristofaro J., et al. Expression of tpo mRNA in thyroid tumors: quantitative PCR analysis and correlation with alterations of ret, Braf, ras and pax8 genes. Endocr. Relat. Cancer 13 (2006) 485-495
72. Holt E. Controversies in the surveillance of patients with well differentiated thyroid cancer. Curr. Opin. Oncol. 19 (2007) 6-10